A comparison of mirtazapine and paroxetine for the treatment of patients with posttraumatic stress disorder: A randomized open-label trial

Clinical Psychopharmacology and Neuroscience

Volumn 8, Issue 2, 2010, Pages 84-89

  Seo, Ho Jun ^a   Jung, Young Eun ^a   Bahk, Won Myong ^a   Jun, Tae Yun ^a   Chae, Jeong Ho ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Efficacy; Mirtazapine; Paroxetine; Posttraumatic stress disorder; Tolerability

Indexed keywords

MIRTAZAPINE; PAROXETINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT RESPONSE;

EID: 77956627817     PISSN: 17381088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., Washington, DC: American Psychiatric Association; 1994.
2. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001;158:1982-1988. (Pubitemid 33104102)
3. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic post-traumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001;62:860-868. (Pubitemid 33131172)
4. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000;283:1837-1844.
5. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001;58:485-492.
6. Davidson JR, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 2003;53: 188-191.
7. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(Suppl 4):19-25.
8. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 2001;62:358-361.
9. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry 2008;69:1404-1415.
10. Bahk WM, Pae CU, Tsoh J, Chae JH, Jun TY, Chul L, et al. Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study. Hum Psychopharmacol 2002;17:341-344.
11. Connor KM, Davidson JR, Weisler RH, Ahearn E. A pilot study of mirtazapine in post-traumatic stress disorder. Int Clin Psychopharmacol 1999;14:29-31. (Pubitemid 29054590)
12. Kim W, Pae CU, Chae JH, Jun TY, Bahk WM. The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24-week continuation therapy. Psychiatry Clin Neurosci 2005;59:743-747.
13. Chung MY, Min KH, Jun YJ, Kim SS, Kim WC, Jun EM. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol 2004;19:489-494.
14. First MB, Spitzer RL, Gibbon M, Williams JBW. Structural Clinical Interview for DSM-IV-Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press; 1997.
15. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, et al. The development of a clinician-administered PTSD Scale. J Trauma Stress 1995;8:75-90.
16. Beck AT, Steer RA, Broen GK. Manual for the beck depression inventory II (BDI-II). San Antonio, Tx: Psychology Corporation; 1996.
17. Guy W. ECDEU assessment manual for psychopharmacology. US department of health, education, and welfare publication (ADM). Washington, DC: National Institute of Mental Health;1976.
18. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986;22:343-381.
19. Behnke K, Søgaard J, Martin S, Bäuml J, Ravindran AV, Agren H, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003;23:358-364.
20. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61:656-663.
21. Marshall RD, Schneier FR, Fallon BA, Knight CB, Abbate LA, Goetz D, et al. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol 1998;18:10-18.
22. Roth S, Newman E, Pelcovitz D, van der Kolk B, Mandel FS. Complex PTSD in victims exposed to sexual and physical abuse: results from the DSM-IV Field Trial for Posttraumatic Stress Disorder. J Trauma Stress 1997;10: 539-555. (Pubitemid 27508855)
23. Deering CG, Glover SG, Ready D, Eddleman HC, Alarcon RD. Unique patterns of comorbidity in posttraumatic stress disorder from different sources of trauma. Compr Psychiatry 1996;37:336-346.